Genta Announces Initial Clinical Trial Results For G4544, A Novel Potent Drug For Bone Disease
Genta Incorporated (OTC Bulletin Board: GNTA) announced the release of final results from the Company's Phase 1 clinical trial of G4544, a proprietary small molecule that is intended as a treatment for diseases associated with accelerated bone loss. Results showed that the drug was very well-tolerated, and that blood levels were achieved in a range that is known to be clinically bioactive.
Hip And Knee Replacement Patients Not Receiving Treatment To Reduce Blood Clot Risk
Hip and knee replacement surgery patients - who are often elderly - are at increased risk of developing potentially life-threatening thrombosis, or blood clots. Nevertheless, according to a study by Dr. Elham Rahme of the Research Institute of the McGill University Health Centre (RI-MUHC) and McGill University, most patients in Quebec do not receive the recommended treatment to prevent a thrombosis.
Bone Pain Can Be A Sign Of Myeloma - Patients And Doctors Join Forces To Raise Awareness Of Early Myeloma Diagnosis
Myeloma Euronet, the European Network of Myeloma Patient Groups, and EFORT, the European Federation of National Associations of Orthopaedics and Traumatology, have joined efforts to highlight the importance of early myeloma diagnosis. A recent international survey1 conducted by Myeloma Euronet among patients and physicians has revealed that advanced disease stage due to late diagnosis constitutes one of the greatest barriers to myeloma treatment and care.
Custom-Fit OtisKnee TM May Impact Early Success Of Total Knee Replacement Surgery, Study Finds
A new study from the University of Alabama at Birmingham indicates that the OtisKnee Custom Fit Knee™ Replacement system may have a positive impact on length of hospital stay, range of motion, pain level and patient satisfaction immediately following total knee replacement surgery.
Depuy Spine Launches Confidence trade; System For Vertebral Compression Fractures At Spineweek
DePuy Spine, Inc., a Johnson & Johnson company, announced the worldwide launch of the CONFIDENCE SPINAL CEMENT SYSTEM™ , a novel treatment for vertebral compression fractures, a painful condition that occurs when one or more vertebrae collapse, usually as a result of osteoporosis.
Potential Therapy Discovered For Hypophosphatasia, A Congenital Form Of Rickets
Researchers at the Burnham Institute for Medical Research, led by Jose Luis Millan, Ph.D., have demonstrated in mice the first successful use of enzyme replacement therapy to prevent hypophosphatasia (HPP), a primary skeletal disease of genetic origin.
Bone Medical Receives FDA Confirmation For Clinical Trial Strategy For Osteoporosis Product
Bone Medical Limited (ASX:BNE) has received clarification from the US FDA for the pivotal trial necessary to obtain approval for its oral calcitonin product, CapsitoninTM. After reviewing the data generated in Bone's recent Phase II study, the FDA has confirmed that CapsitoninTM is eligible for registration via a 505(b)(2) pathway.
Chimp Receives Surgery From A UK Orthopedic Surgeon To Correct A Deformity
An orthopaedic surgeon at the University of Liverpool has performed a groundbreaking operation on a chimp in Cameroon to correct a deformity more commonly seen in dogs.The three year-old chimp called Janet was rescued from the Cameroon pet trade last year and now lives in a chimpanzee reserve supported by the Cameroon Wildlife Aid Fund.
Women Underestimate Their Risk Of Spinal Fractures From Osteoporosis, Reveals A Spine-health.com Study
A study by Spine-health.com, the leading health website for people with back pain and other pain conditions, reveals that women with back pain underestimate their risk of spinal fractures. The study, based on a recent survey conducted on http://www.
Denosumab Achieved Superior Bone Mineral Density Gains In Head-To-Head Trial Versus Weekly Alendronate Fosamax
Amgen (NASDAQ: AMGN) announced complete results from a head-to-head, double-blind study comparing the effects of twice-yearly subcutaneous injections of denosumab versus weekly oral doses of alendronate (FOSAMAX) on bone mineral density (BMD) in postmenopausal women with low BMD.